The FDA has approved Soliris (eculizumab; Alexion Pharmaceuticals, Inc) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Results from the small study are promising.
In women with NMOSD, 42.9% of pregnancies ended in miscarriage compared with 12-24% in the general population.
Those treated with levodopa saw macular degeneration onset later than controls.
Optic ultrasound is a fast and easy, noninvasive way to measure intracranial pressure.
An anti-LINGO-1 monoclonal antibody showed some success in treating optic neuritis but missed many study endpoints.
Mycophenolate mofetil effectively eliminated relapses in 60% of patients with neuromyelitis optica spectrum disorder.
Multiple sclerosis patients with uveitis tend to be female and older in age, according to new research.
Visual assessments are useful in evaluating minor traumatic brain injury in the field as well as for the understanding of long-term repercussions.